Congratulations to the team at Alesta Therapeutics on raising an impressive €65 million in their Series A financing! Led by Frazier Life Sciences and Droia Ventures, this round will push their work in rare disease therapies to new levels.
Their lead program, ALE1, targets hypophosphatasia (HPP), a rare genetic disorder, with plans to enter clinical trials in 2025. With a second program addressing Charcot-Marie-Tooth (CMT), Alesta is on a mission to transform patient care in underserved areas.
This milestone shows how innovative science, dedicated leadership, and collaboration with global experts lead to impactful results.
We’re excited to see how this funding accelerates their work to deliver life-changing therapies. And we’re proud to see a company in our community thrive on its journey to make a difference in patients’ lives globally.
Huge congrats to the Alesta team and their partners for this incredible achievement!
Read the full press release here
This summer, students and professionals passionate about pharmaceutical innovation have a unique opportunity to gain hands-on experience in modern drug development. The...
To help address the growing need for well-trained production personnel in the Life Sciences industry, Talentmark and Biotech Training Facility (BTF) are joining forces to...
From 6–9 May 2025, the Netherlands Embassy in Seoul, in collaboration with the Netherlands Enterprise Agency (RVO), is organising a trade mission to South Korea focused on the...